Zacks: Analysts Set $100.00 Price Target for Steris Plc (STE)
Steris Plc (NYSE:STE) has been assigned an average broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Analysts have set a one year consensus price target of $100.00 for the company and are predicting that the company will post $1.07 earnings per share for the current quarter, according to Zacks. Zacks has also given Steris Plc an industry rank of 161 out of 265 based on the ratings given to its competitors.
STE has been the topic of a number of research analyst reports. KeyCorp restated an “overweight” rating and issued a $101.00 price target (up from $91.00) on shares of Steris Plc in a report on Thursday, November 2nd. Zacks Investment Research cut shares of Steris Plc from a “buy” rating to a “sell” rating in a report on Monday, November 6th. TD Securities upped their price target on shares of Steris Plc from C$14.00 to C$16.00 and gave the stock a “buy” rating in a report on Thursday. Raymond James Financial, Inc. upped their price target on shares of Steris Plc from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, August 9th. Finally, BidaskClub cut shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st.
Steris Plc (STE) traded down C$1.30 during mid-day trading on Monday, reaching C$86.85. 235,400 shares of the company’s stock were exchanged, compared to its average volume of 475,037. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.80 and a quick ratio of 2.18. Steris Plc has a fifty-two week low of C$64.37 and a fifty-two week high of C$93.39. The company has a market capitalization of $7,386.80, a PE ratio of 22.38 and a beta of 1.31.
Steris Plc (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 1st. The company reported C$0.94 earnings per share for the quarter, missing the Zacks’ consensus estimate of C$0.95 by C($0.01). Steris Plc had a net margin of 5.59% and a return on equity of 11.49%. The firm had revenue of C$634.20 million for the quarter, compared to the consensus estimate of C$629.02 million. During the same quarter last year, the firm earned $0.89 EPS. The company’s revenue was down 1.9% on a year-over-year basis. equities research analysts forecast that Steris Plc will post 4.06 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 20th. Shareholders of record on Wednesday, November 22nd will be given a dividend of $0.31 per share. This represents a $1.24 annualized dividend and a dividend yield of 1.43%. The ex-dividend date of this dividend is Tuesday, November 21st. Steris Plc’s payout ratio is 73.81%.
In related news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of C$85.69, for a total value of C$856,900.00. Following the completion of the transaction, the chief executive officer now directly owns 83,270 shares of the company’s stock, valued at approximately C$7,135,406.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Karen L. Burton sold 3,270 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of C$85.70, for a total transaction of C$280,239.00. Following the completion of the transaction, the vice president now directly owns 11,807 shares of the company’s stock, valued at C$1,011,859.90. The disclosure for this sale can be found here. Insiders sold a total of 202,342 shares of company stock valued at $17,729,692 over the last ninety days. 2.55% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the stock. State of Wisconsin Investment Board acquired a new position in Steris Plc in the 2nd quarter worth approximately $1,360,000. First Trust Advisors LP increased its holdings in Steris Plc by 84.6% in the 2nd quarter. First Trust Advisors LP now owns 15,865 shares of the company’s stock worth $1,293,000 after buying an additional 7,272 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Steris Plc by 1.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 122,520 shares of the company’s stock worth $9,986,000 after buying an additional 1,963 shares during the period. Koch Industries Inc. acquired a new position in Steris Plc in the 2nd quarter worth approximately $1,089,000. Finally, GWM Advisors LLC increased its holdings in Steris Plc by 59.8% in the 2nd quarter. GWM Advisors LLC now owns 6,741 shares of the company’s stock worth $553,000 after buying an additional 2,522 shares during the period. Institutional investors own 93.50% of the company’s stock.
WARNING: “Zacks: Analysts Set $100.00 Price Target for Steris Plc (STE)” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/zacks-analysts-set-100-00-price-target-for-steris-plc-ste/1700208.html.
About Steris Plc
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.